Russia’s Sechenov first Moscow State medical University has recently announced it’s completion of the world’s first clinical trials of coronavirus vaccine on humans successfully, on July 12, 2020. News state, Vadim Tarasov, the director of Translational Medicine and Biotechnology, told that the University has finished the immunization sample tests on participants of the world`s first vaccine against covid-19.
The clinical data collected by the Gamalei National Research Center for Epidemiology and Microbiology is conspicuous that volunteers of the first and second groups are showing markedly good immune response and are ready to be discharged. Gamalei research centre’s director Alexander Gintsburg stated in a press meet that he anticipates that the vaccine would launch in the commercial market in mid August i.e around 12-14, by mentioning that companies may begin bulk production on larger scale by September.
While on the flip side the protocol draft for COVID-19 candidate vaccines propounded by the World Health Organization (WHO) mentions the Russian coronavirus vaccine research as a phase 1 trial. Reportedly, WHO data as per July 7th reveals the only eligible candidates to reach phase 3 trials were Oxford/AstraZeneca’s ChAdOx1-S and Sinovac’s vaccine.
WHO protocol proves that a vaccine ought to complete three phases of studies before proceeding for large-scale production. A candidate vaccine usually gets green signal for comercial production if the last phase shows right evidence of its safety and efficaciousness without adverse effects.